MA29353B1 - Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines - Google Patents

Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines

Info

Publication number
MA29353B1
MA29353B1 MA30254A MA30254A MA29353B1 MA 29353 B1 MA29353 B1 MA 29353B1 MA 30254 A MA30254 A MA 30254A MA 30254 A MA30254 A MA 30254A MA 29353 B1 MA29353 B1 MA 29353B1
Authority
MA
Morocco
Prior art keywords
dementia
parkinson
disease
treatment
sleep apnea
Prior art date
Application number
MA30254A
Other languages
English (en)
French (fr)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29353(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MA29353B1 publication Critical patent/MA29353B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA30254A 2005-04-01 2007-09-27 Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines MA29353B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
MA29353B1 true MA29353B1 (fr) 2008-03-03

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30254A MA29353B1 (fr) 2005-04-01 2007-09-27 Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines

Country Status (27)

Country Link
US (1) US8486947B2 (https=)
EP (2) EP1707203A1 (https=)
JP (3) JP5546761B2 (https=)
KR (1) KR101308527B1 (https=)
CN (1) CN101171009B (https=)
AU (1) AU2006228413C1 (https=)
BR (1) BRPI0612216B1 (https=)
CA (1) CA2603656C (https=)
CY (1) CY1114636T1 (https=)
DK (1) DK1863487T4 (https=)
EA (1) EA016007B1 (https=)
ES (1) ES2426008T5 (https=)
HR (1) HRP20130748T4 (https=)
MA (1) MA29353B1 (https=)
ME (1) ME01713B (https=)
MX (1) MX2007012162A (https=)
NO (1) NO343603B1 (https=)
NZ (1) NZ561940A (https=)
PL (1) PL1863487T5 (https=)
PT (1) PT1863487E (https=)
RS (1) RS52911B2 (https=)
SG (1) SG147415A1 (https=)
SI (1) SI1863487T2 (https=)
TN (1) TNSN07365A1 (https=)
UA (1) UA94902C2 (https=)
WO (1) WO2006103546A2 (https=)
ZA (1) ZA200708086B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HK1207004A1 (zh) * 2012-10-05 2016-01-22 Vtv治疗有限责任公司 治療輕度和中度阿爾茨海默病的方法
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11654283B2 (en) 2019-03-06 2023-05-23 Medtronic Xomed, Inc. Obstructive sleep apnea patient programmer for implantable devices
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
CN121175294A (zh) 2023-03-31 2025-12-19 生物计划制药公司 盐酸替洛利生的多晶型形式
WO2025082972A1 (en) * 2023-10-16 2025-04-24 Bioprojet Pharma Enteric coated pitolisant formulations and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JPH06505265A (ja) 1991-02-27 1994-06-16 シード・キャピタル・インベストメント・（エス・シー・アイ）・ベスローテン・フェンノートシャップ ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
DE69212164T2 (de) 1991-12-18 1996-12-05 Schering Corp., Kenilworth, N.J. Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
MX9207393A (es) 1991-12-18 1994-06-30 Schering Corp Imidazoil o alquilo de imidazoil susbtituido con una cadena heterociclica de cuatro o cinco miembros que contienen nitrogeno.
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
WO1994017058A1 (fr) 1993-01-25 1994-08-04 The Green Cross Corporation Compose d'imidazole
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
WO1995006037A1 (en) 1993-08-27 1995-03-02 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK0841922T3 (da) 1995-05-30 2002-06-03 Gliatech Inc 1H-4(5)-substituerede imidazolderivater
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
DK0841923T3 (da) 1995-06-07 2003-01-27 Gliatech Inc 1H-4(5)-substituerede imidazolderivater
RU2182904C2 (ru) 1996-02-09 2002-05-27 Джеймс Блэк Фаундейшн Лимитед Сульфонамиды и способы их получения
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
WO2000076957A1 (en) * 1999-06-11 2000-12-21 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
WO2002013821A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
EP1373218B9 (en) * 2001-03-29 2008-12-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Imidazolyl derivatives useful as histamine h3 receptor ligands
EP1451225A1 (en) * 2001-11-15 2004-09-01 Ortho-McNeil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
PT1451167E (pt) * 2001-12-10 2006-07-31 Ortho Mcneil Pharm Inc Fenilalcinos
US7279491B2 (en) * 2002-10-23 2007-10-09 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines
EP1642898B1 (en) * 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative

Also Published As

Publication number Publication date
CN101171009B (zh) 2012-11-07
SI1863487T2 (sl) 2019-11-29
CY1114636T1 (el) 2016-10-05
EP1707203A1 (en) 2006-10-04
PL1863487T5 (pl) 2021-08-09
US8486947B2 (en) 2013-07-16
KR101308527B1 (ko) 2013-09-17
SI1863487T1 (sl) 2013-09-30
MX2007012162A (es) 2007-11-22
RS52911B2 (sr) 2019-11-29
CA2603656C (en) 2015-06-16
ES2426008T3 (es) 2013-10-18
UA94902C2 (ru) 2011-06-25
DK1863487T4 (da) 2019-10-14
CN101171009A (zh) 2008-04-30
JP2014062126A (ja) 2014-04-10
DK1863487T3 (da) 2013-08-12
ME01713B (me) 2014-09-20
EP1863487B2 (en) 2019-07-17
BRPI0612216B1 (pt) 2022-04-19
US20090318433A1 (en) 2009-12-24
SG147415A1 (en) 2008-11-28
BRPI0612216A2 (pt) 2010-10-26
WO2006103546A2 (en) 2006-10-05
HRP20130748T4 (hr) 2019-11-15
PT1863487E (pt) 2013-08-29
NZ561940A (en) 2010-06-25
JP5955872B2 (ja) 2016-07-20
HRP20130748T1 (en) 2013-10-11
EA200702135A1 (ru) 2008-04-28
ES2426008T5 (es) 2020-03-20
AU2006228413C1 (en) 2012-02-02
RS52911B (sr) 2014-02-28
JP5546761B2 (ja) 2014-07-09
EP1863487A2 (en) 2007-12-12
AU2006228413B2 (en) 2011-09-15
PL1863487T3 (pl) 2014-10-31
WO2006103546A3 (en) 2007-03-01
AU2006228413A1 (en) 2006-10-05
EA016007B1 (ru) 2012-01-30
NO343603B1 (no) 2019-04-08
JP2016106142A (ja) 2016-06-16
CA2603656A1 (en) 2006-10-05
KR20080002904A (ko) 2008-01-04
JP2008534572A (ja) 2008-08-28
TNSN07365A1 (fr) 2008-12-31
NO20075086L (no) 2007-12-27
EP1863487B1 (en) 2013-05-29
ZA200708086B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
TNSN07365A1 (fr) Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines
CY1122724T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
EP2119443A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO A THROMBUS OR EMBOLUS
WO2006117609A3 (en) Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3 -receptor ligands
CY2015025I1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
IL194947A0 (en) Aryl-4-ethynyl-isoxazole derivatives
WO2004074246A3 (en) Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
EP4034530A4 (en) INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASES
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EP1807396A4 (en) 2-AMINOPYRIDINE COMPOSITIONS AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
MY137272A (en) Imidazole derivatives
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2011036297A3 (de) Verfahren zur therapie und diagnose von morbus alzheimer
EP1814537A4 (en) MACROCYCLIC TERTIARY AMIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
GB202016425D0 (en) Treatment regimens for parkinson's disease
EA200701984A1 (ru) Конденсированные тиазольные производные, обладающие сродством к гистаминовому h3 рецептору
EP1813596A4 (en) PROCESS FOR PREPARING ALPHA, ALPHA-DIFLUORAMINE
FR2905290B1 (fr) Dispositif de traitement pour le grenaillage de la surface interieure d'une piece tubulaire